新标准-话题@MedSci

#新标准#

47篇内容 | 1077人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1935278, encodeId=0b5e19352e8eb, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=Lancet neurology：脑淀粉样血管病的波士顿标准2.0版新标准研究, objectType=article, longId=734083, objectId=18ebe34083fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ebe34083fa, replyNumber=0, likeNumber=52, createdTime=2022-08-13, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ebe34083fa, moduleTitle=Lancet neurology：脑淀粉样血管病的波士顿标准2.0版新标准研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ebe34083fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2140114, encodeId=8a1f214011443, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a><a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=Transl, objectType=topic, longId=17755, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=41, createdTime=2023-05-31, rootId=0, userName=ms7000001761632080, userId=c0c08185654, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935277, encodeId=531d19352e787, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=国家卫健委官发布：转诊有了新标准！, objectType=article, longId=300389, objectId=68103003890e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68103003890e, replyNumber=0, likeNumber=42, createdTime=2022-06-28, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68103003890e, moduleTitle=国家卫健委官发布：转诊有了新标准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68103003890e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935274, encodeId=0a0719352e44a, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=国家药监局发文：77项医疗器械行业全新标准来了！, objectType=article, longId=211912, objectId=b775211912e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b775211912e9, replyNumber=0, likeNumber=43, createdTime=2022-01-01, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b775211912e9, moduleTitle=国家药监局发文：77项医疗器械行业全新标准来了！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b775211912e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935275, encodeId=548519352e5bc, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, objectType=article, longId=212418, objectId=8c9f212418e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c9f212418e1, replyNumber=0, likeNumber=42, createdTime=2021-08-17, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c9f212418e1, moduleTitle=ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c9f212418e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935276, encodeId=7f5b19352e661, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, objectType=article, longId=213189, objectId=500e213189ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=500e213189ee, replyNumber=0, likeNumber=43, createdTime=2021-09-09, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=500e213189ee, moduleTitle=Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=500e213189ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935273, encodeId=e1b219352e3ab, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=Translational Psychiatry：血清素或可成为抑郁症疗效新标准, objectType=article, longId=211156, objectId=232f211156d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=232f211156d0, replyNumber=0, likeNumber=50, createdTime=2021-11-10, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=232f211156d0, moduleTitle=Translational Psychiatry：血清素或可成为抑郁症疗效新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=232f211156d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935272, encodeId=c82119352e22a, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=服药后肿瘤增大，说明抗癌药无效？吴一龙教授：应看这个新标准, objectType=article, longId=206487, objectId=a66c20648e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a66c20648e50, replyNumber=0, likeNumber=38, createdTime=2021-02-09, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a66c20648e50, moduleTitle=服药后肿瘤增大，说明抗癌药无效？吴一龙教授：应看这个新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a66c20648e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935271, encodeId=316a19352e18b, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, objectType=article, longId=194365, objectId=0d90194365fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d90194365fe, replyNumber=0, likeNumber=32, createdTime=2021-01-08, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d90194365fe, moduleTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d90194365fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935268, encodeId=1b8c19352687e, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, objectType=article, longId=183912, objectId=fc8b1839120b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc8b1839120b, replyNumber=0, likeNumber=34, createdTime=2020-06-24, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc8b1839120b, moduleTitle=中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc8b1839120b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935270, encodeId=03f019352e0b3, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=乳腺癌规范化治疗更上一层楼！李俊杰教授详细解读乳腺癌新辅助诊疗新标准, objectType=article, longId=193126, objectId=941b1931264a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941b1931264a, replyNumber=0, likeNumber=57, createdTime=2020-05-25, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941b1931264a, moduleTitle=乳腺癌规范化治疗更上一层楼！李俊杰教授详细解读乳腺癌新辅助诊疗新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941b1931264a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935264, encodeId=850f1935264a4, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=ASCO 2019：骨靶向药物的降级方案有望成为肿瘤骨转移治疗的新标准, objectType=article, longId=167884, objectId=b24b16e88441, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b24b16e88441, replyNumber=0, likeNumber=33, createdTime=2019-09-12, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b24b16e88441, moduleTitle=ASCO 2019：骨靶向药物的降级方案有望成为肿瘤骨转移治疗的新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b24b16e88441)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935269, encodeId=a9c919352692e, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=【ESMO ASIA】中国数据助力亚洲乳腺癌辅助治疗新标准, objectType=article, longId=184049, objectId=efd4184049ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efd4184049ed, replyNumber=0, likeNumber=50, createdTime=2020-08-24, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efd4184049ed, moduleTitle=【ESMO ASIA】中国数据助力亚洲乳腺癌辅助治疗新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efd4184049ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935265, encodeId=5332193526561, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=吴一龙教授：Ⅲ期不可切除NSCLC治疗新标准确立后的重新审视, objectType=article, longId=172152, objectId=42101e215298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42101e215298, replyNumber=0, likeNumber=0, createdTime=2020-01-29, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42101e215298, moduleTitle=吴一龙教授：Ⅲ期不可切除NSCLC治疗新标准确立后的重新审视, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42101e215298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935266, encodeId=a8a819352667c, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=40, createdTime=2019-11-07, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935267, encodeId=525a193526e89, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, objectType=article, longId=180959, objectId=d44c18095907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44c18095907, replyNumber=0, likeNumber=37, createdTime=2020-07-26, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44c18095907, moduleTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44c18095907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935263, encodeId=77e51935263bf, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=江苏医疗安保新规2月1日施行保安员配备有新标准, objectType=article, longId=158691, objectId=14b615869181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b615869181, replyNumber=0, likeNumber=38, createdTime=2019-02-15, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b615869181, moduleTitle=江苏医疗安保新规2月1日施行保安员配备有新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b615869181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935262, encodeId=839f1935262c0, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=美国糖尿病协会发布2019版新标准：强调减肥、戒烟、不喝甜饮料，胰岛素退居二线, objectType=article, longId=156321, objectId=0504156321ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0504156321ae, replyNumber=0, likeNumber=74, createdTime=2019-05-25, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0504156321ae, moduleTitle=美国糖尿病协会发布2019版新标准：强调减肥、戒烟、不喝甜饮料，胰岛素退居二线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0504156321ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935260, encodeId=e7d21935260ff, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=RECIL 2017：淋巴瘤试验中疗效评估新标准, objectType=article, longId=143692, objectId=131214369216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=131214369216, replyNumber=0, likeNumber=31, createdTime=2018-11-03, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=131214369216, moduleTitle=RECIL 2017：淋巴瘤试验中疗效评估新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=131214369216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1935259, encodeId=5c591935259eb, content=<a href='/topic/show?id=ab995841480' target=_blank style='color:#2F92EE;'>#新标准#</a>, objectTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, objectType=article, longId=131089, objectId=56eb131089ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56eb131089ae, replyNumber=0, likeNumber=45, createdTime=2018-08-25, rootId=0, userName=xiaoyang_ambs, userId=4736501, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56eb131089ae, moduleTitle=Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56eb131089ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新标准

2020-05-29

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

Lancet neurology：脑淀粉样血管病的波士顿标准2.0版新标准研究

2022-08-13

ms7000001761632080 (审核中...)

前往app查看评论内容

#Transl##新标准#

2023-05-31

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

国家卫健委官发布：转诊有了新标准！

2022-06-28

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

国家药监局发文：77项医疗器械行业全新标准来了！

2022-01-01

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

ASCO 2021：中国之声！特瑞普利单抗一线治疗复发/转移性鼻咽癌研究取得突破性进展，有望改写国际新标准！

2021-08-17

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

Lancet oncol：卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

2021-09-09

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

Translational Psychiatry：血清素或可成为抑郁症疗效新标准

2021-11-10

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

服药后肿瘤增大，说明抗癌药无效？吴一龙教授：应看这个新标准

2021-02-09

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批

2021-01-08

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

中国晚期肺鳞癌患者迎一线治疗新标准，帕博利珠单抗新适应证获批意义重大

2020-06-24

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

乳腺癌规范化治疗更上一层楼！李俊杰教授详细解读乳腺癌新辅助诊疗新标准

2020-05-25

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

ASCO 2019：骨靶向药物的降级方案有望成为肿瘤骨转移治疗的新标准

2019-09-12

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

【ESMO ASIA】中国数据助力亚洲乳腺癌辅助治疗新标准

2020-08-24

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

吴一龙教授：Ⅲ期不可切除NSCLC治疗新标准确立后的重新审视

2020-01-29

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-11-07

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准

2020-07-26

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

江苏医疗安保新规2月1日施行保安员配备有新标准

2019-02-15

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

美国糖尿病协会发布2019版新标准：强调减肥、戒烟、不喝甜饮料，胰岛素退居二线

2019-05-25

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

RECIL 2017：淋巴瘤试验中疗效评估新标准

2018-11-03

xiaoyang_ambs (审核中...)

前往app查看评论内容

#新标准#

Lancet Oncol：卡波铂+ veliparib对三阴性乳腺癌高危患者新标准化疗效果的影响

2018-08-25

科室
- - 订阅+
  - 更多科室
工具
服务